The Institute of Cancer Research
HomepageIndexSearchFeedbackSite MapContact Us

About Us

Research

Research Groups
Physics
Research Report

Publications
Research Grants
Seminars
Organisations

Education

Support Us

Cancer Information

Press

Jobs

Partners and Funders
Quick Search


Research

Research Groups: Joint Department of Physics

RADIOTHERAPY PHYSICS TEAM - Chelsea
Head of Clinical and Research Radiotherapy Physics
A M Bidmead MSc

 


The Clinical and Research Radiotherapy Physics Groups have been commissioning a new radiotherapy simulator with an amorphous silicon image capture system to replace a bulky more conventional image intensifier. The new machine allows digital images to be acquired, used as reference images for EPI verification and transferred throughout the whole radiotherapy department via the network. The more automated system improves patient throughput on the simulator and provides good image quality. The various IMRT clinical studies are recruiting well, and additional clinical sites are being added regularly. Electronic portal imaging, using the amorphous silicon detector, is used routinely to evaluate the patient set up and research is being performed on the use of such a system for dosimetry and IMRT verification. The implementation of Head and Neck IMRT has lead to evaluation and re-design of some immobilisation devices. The design of an IMRT trial for head and neck and parotid irradiation in collaboration with other European centres is ongoing.

SUMMARY OF RESEARCH ACTIVITY:

Volume Definition and Exchange of Contours (Sutton and Chelsea)
Stefano Gianolini, Elizabeth J Adams, James L Bedford, Cephas D Mubata, Rollo Moore, Alan Nahum, AMargaret Bidmead; in collaboration with David P Dearnaley, Urology and Testicular Cancer Unit. Source of funding: Urology and Testicular Cancer Unit, MRC, The Royal Marsden
An independent DICOM agent has been set up to allow CT data to be transferred between different commercial treatment-planning systems. Computer software has been written to allow the transfer of contours in conjunction with these images and this work is now being used with the data from the quality assurance study of the RT01 national MRC prostate trial. The development of "Guinnes" has improved the flexibility of this system and more treatment- planning system communication is now available. It has provided links to radiobiological modelling software written by members of the Dose Modelling Group.

Reduction of Heart Dose in Breast Radiotherapy
Colin A Nalder, John Pettingell, Chris Fall; in collaboration with L Viviers, GM Ross, Section of Radiotherapy.; Source of funding: The Royal Marsden
A new CT planning position for breast radiotherapy with the use of a commercial breast board system is being investigated to try to reduce heart irradiation in breast radiotherapy. The addition of MLC conformal shielding, without compromise of PTV coverage, reduces dose to the heart significantly. Evaluation of the contouring device "OSIRIS" is being undertaken by comparison with CT scan data of patients in the new treatment position. Both accuracy of contour and prediction of lung position are being assessed.

Comparison and Optimisation of Breast Plans with Patient in CT position
Sara Alonso-Arrizabalaga, Catharine Clark, Colin A Nalder, John Pettingell, Chris Fall; in collaboration with L Viviers, GM Ross, Section of Radiotherapy
Source of funding: The Royal Marsden, Varian Oncology Systems
CT data obtained for the previous study is also being used for the production and evaluation of optimised treatment plans for uniform and boost, breast irradiation, whilst sparing lung and cardiac surfaces. Various treatment plans have been produced for contoured PTV's and a comparison of techniques is underway.

Prostate Dose Escalation Study - RT01 [Project No.1460]
Rollo Moore, Caroline Lamb, Claire Banks, Sara Alonso, Maragret Bidmead, Colin Nalder, Carole Meehan, John Pettingell, Cephas Mubata; in collaboration with DP Dearnaley, Urology and Testicular Cancer Unit. Source of funding: The Royal Marsden, Urology and Testicular Cancer Unit, MRC
The quality assurance analysis of the three-dimensional treatment-planning process for RT01 patients is centred at The Royal Marsden. The Radiotherapy Physics Group is acting as the reference centre for quality assurance and is evaluating data from all the participating centres. A detailed quality-assurance program has been developed and site visits have been be made to all participating centres. In addition, treatment plans and dose-volume histograms are being collated and evaluated from the six different computer planning systems in use at the different centres for this trial.

Stereotactic Radiotherapy
Kevin Burke, Colin Nalder, T. Ajithkumar. Source of funding: The Royal Marsden; Neuro-Oncology Unit
Stereotactic radiotherapy continues to be offered as a standard form of treatment for brain tumours. A dedicated radiotherapy research registrar is in post to investigate further applications of the stereotactic system and to evaluate geometric uncertainties involved in patient set-up and treatment delivery using DRR's and electronic portal imaging. This data will contribute to geometric set-up uncertainty data being reviewed by the BIR in the context of ICRU 62.

Brachytherapy Research and Development
Margaret Bidmead, Colin Nalder, Margarida Fragoso,; in collaboration with PR Blake, D Barton, Gynaecology Unit. Source of funding: The Royal Marsden, C UK
New software which allows CT input of patients with brachytherapy applicators in place is being evaluated. This software also has different methods of dosimetry calculation which are under development in collaboration with the manufacturer. Patients who have had previous radiotherapy to the pelvis can be re-treated with the intra-operative placement of catheters for the afterloading of high-dose-rate iridium to give a dose distribution specifically designed to conform to the tumour bed whilst sparing surrounding normal tissues. A series of selected patients are being treated by this method, which is continuously evolving and patient follow-up is being maintained.

Portal Imaging
Carole Meehan, Cephas Mubata, Kevin Burke, Margaret Bidmead
Source of funding: The Royal Marsden
Continuing commercial collaboration with Varian Oncology Systems has provided new image matching software which is being evaluated and compared with existing software. Implementation of reference images direct from the new Acuity Simulator form part of this recent evaluation. Use of DRR's for prostate and brain verification are now routine.

Assessment of Immobilisation Shells for the Treatment of Head and Neck Patients with IMRT
Mandy Humphreys, Helen Convery, Margaret Bidmead, Cephas Mubata
Source of funding: The Royal Marsden
Verification of patient position using an orthogonal pair of images has been developed to assess the reproducibility of immobilisation with particular reference to the neck region. This is to assess the "goodness of fit" of the radiotherapy shell around the shoulder area and thus the immobilisation of the spinal cord, in preparation for IMRT treatment delivery. When identifying nodes and possibly escalating dose to these areas immobilisation is crucial. Orthogonal images are acquired on the first five days of treatment and matched. If positional reproducibility is good then images are taken at weekly intervals. The high resolution of the amorphous silicon detector allows accurate comparisons of anatomical position to be made.

Evaluation of Monte-Carlo Dose Computation in a Commercial Treatment-planning System
Colin Nalder, Cephas Mubata, Joao Seco, Stefano Gianolini, Alan Nahum, Margaret Bidmead, David Dance. Source of funding: The Royal Marsden
The extensive development work already done by the Monte-Carlo group on Monte-Carlo based dose computation using the EGS/BEAM system is now ready for clinical evaluation via a comparison of Monte-Carlo based plans with those generated in the CADPLAN (Fulham Rd) and PINNACLE (Sutton) commercial treatment planning systems. A user-friendly interface to these TPSs is under development. A number of treatment plans will be analysed in this manner, in terms not only of differences in 3D dose distribution (relative and absolute) and Dose-Volume Histograms but also using so-called biological models employing the GUINESS dose distribution analysis software (developed by Dr S Gianolini).

Simulation of Intensity-Modulated Radiotherapy by Monte-Carlo
Joao Seco, Alan E Nahum, Steve Webb, Margaret Bidmead, David R Dance; in collaboration with Frank Verhaegen, NPL, Teddington
Source of funding: EPSRC, The Royal Marsden, The Institute
Monte-Carlo simulation is being applied to all the stages in the delivery of Radiotherapy by intensity-modulated high-energy photon beams: the creation of the intensity variation by means of a multileaf collimator, whether statically or dynamically, comparison of this with the desired photon-fluence profile, and the resulting dose distribution in the patient and its differences compared to the predictions of the treatment-planning systems at Sutton and at Fulham Rd. This project builds on the accelerator-modelling work done by Dr F Verhaegen and uses the cluster of PCs developed by Dr P Love during 1999-2000. The software platform is currently the EGS/BEAM system, though more efficient alternatives are being explored.

Development of 3D Models for the Accurate Integration of CT-based Brachytherapy and External-beam Treatment Planning
Margarida Fragoso, Margaret Bidmead, Alan Nahum; in collaboration with F Verhaegen, NPL, Teddington;C Deehan, Medical Physics, Leicester; D Hill, Medical Physics Department, GKT, London. Source of funding: The Institute
Patient position is radically different between brachytherapy for cervical cancer involving caesium sources and external-beam therapy. It has been shown that this "anatomical distortion" can be only partially "corrected" using sophisticated voxel-based image deformation software developed by the medical imaging research group at Guy's Hospital. Monte-Carlo methods are being applied to the brachytherapy dose distributions, thus accounting for both the detailed geometry of the sources and the effect of patient heterogeneity described by CT; a model of the phase-space of particles on the surface of an applicator has been implemented as the starting point for the simulation of the radiation transport in the full heterogeneous geometry of the patient. Radiobiologically based "correction" of the brachytherapy dose delivery in order that it may be added to the 2Gy fractionated external-beam delivery will also be carried out.

Monte-Carlo Simulation of Ionisation Chamber Response using the EGSnrc Code
Alan E Nahum, Margarida Fragoso. Source of funding: The Institute
Recent improvements to electron transport within the EGS code system (namely the option of switching between condensed-history and interaction-by-interaction or analogue simulation of the elastic scattering events close to media boundaries) promise to remove the previous difficulties encountered when simulating ion chamber response in megavoltage photon and electron beams. In particular previous versions of EGS4/PRESTA failed to predict the measured change in response of an aluminium-walled chamber in a Co-60 beam due to the addition of extremely thin layers of dag (graphite in liquid form). We are currently performing simulations of this chamber geometry using the EGSnrc code; preliminary results indicate that all the problems have not yet been resolved.

A phase I dose escalation study of the use of Intensity Modulated Radiotherapy (IMRT) to treat the prostate and pelvic nodes in patients with localised prostate cancer.
Catharine Clark, Teresa Guerrero-Urbano, John Staffurth, Cephas Mubata, Carole Meehan, Elizabeth Miles, Margaret Bidmead, David Dearnaley
Source of funding: The Royal Marsden, Varian Oncology Systems
The Cadplan Helios inverse treatment-planning system has been used to plan simultaneous boost IMRT for patients with cancer of the prostate and pelvic nodes. This is part of a phase I dose escalation trial to investigate the benefits of increasing the dose to the pelvic nodes from 50 Gy to 55 Gy and then to 60 Gy. The second level of escalation has begun and the third level is envisaged to begin in early 2003.

A phase I/II dose escalation study for treatment of patients with carcinoma of the thyroid and cervical nodes
Catharine Clark, Teresa Guerrero-Urbano, Elizabeth Miles, Cephas Mubata, Margaret Bidmead, Mandy Humphreys, Helen McNair, Kevin Harrington and Chris Nutting. Source of funding: The Royal Marsden, Varian Oncology Systems
External beam radiotherapy for cancer of the thyroid poses a difficult challenge, due to the proximity of the target volume to the spinal cord. IMRT allows the sparing of the spinal cord whilst achieving superior dose coverage to both the thyroid and the surrounding involved nodes. The aim of this study was to design a class solution suitable for delivering IMRT on our 2100C/D Varian linac, as well as establishing methods for verifying the dose and fluence for this technique. This work found that IMRT offers improved target homogeneity in patients with thyroid carcinoma as well as reducing the dose to the spinal cord. In particular, the increased minimum dose within the PTV should increase tumour control probability. We have designed a 5-field IMRT technique with asymmetric posterior oblique fields which provides sparing of the spinal cord whilst maintaining acceptable coverage of the thyroid and PTV targets. Following this study, treatment of thyroid patients using this IMRT technique has started as part of an approved clinical trial. Dose escalation from the current level of 58.8 Gy to 66.6 Gy to the thyroid will be the next step in this trial.

Intensity Modulated Radiotherapy (IMRT) to improve target coverage, spinal cord sparing and allow dose escalation in patients with cancer of the larynx
Catharine Clark, Teresa Guerrero-Urbano, Elizabeth Miles, Margaret Bidmead, Cephas Mubata, Kevin Harrington, Peter Rhys Evans and Chris Nutting
Source of funding: The Royal Marsden, Varian Oncology Systems
An investigation has been carried out into the potential for IMRT to improve the coverage of the target and the sparing of the spinal cord in radiotherapy treatment of the larynx and bilateral cervical lymph nodes. In an initial study, conventional and IMRT plans were produced for six patients to treat the larynx to 65Gy and the lymph nodes to 50Gy. The potential to escalate the dose to both the larynx and the nodes was investigated for the IMRT plans. It was found that IMRT offers improved target homogeneity and reduces irradiation of the spinal cord. This sparing of normal tissue structures is sufficient that significant dose-escalation of both the larynx and lymph nodes may be possible without any predicted increase in normal tissue complication probability. Following this study patients are now being treated in the clinic. Once the treatment technique has been established then the dose will be escalated to 67.2 Gy to the larynx PTV and 56.0 Gy to the lymph nodes in 28 fractions.

A phase III Parotid sparing trial for patients with head and neck cancer
Catharine Clark, Teresa Guerrero-Urbano, Elizabeth Miles, Colin Nalder, Cephas Mubata, Margaret Bidmead, Kevin Harrington, and Chris Nutting
Source of funding: The Royal Marsden, Varian Oncology Systems
A study has started to investigate treating head and neck patients whilst sparing the parotid glands. This will be part of a Phase III trial. The patients will be randomised between a conventional and an IMRT technique. In an initial study, conventional and IMRT plans were produced for five patients to treat the high dose region to 65Gy and the lymph nodes to 54Gy in 30 fractions. It was found that IMRT offers improved target homogeneity and significantly reduces irradiation of the parotid glands. This is expected to improve the patients' quality of life by reducing the incidence of dry mouths which is a common side effect of parotid irradiation. An IMRT planning and QA protocol was designed. Following this study patients are now being treated in the clinic.

A randomised pilot study of high dose hypofractionated conformal radiotherapy in localised prostate cancer
Catharine Clark, Teresa Guerrero-Urbano, Elizabeth Miles, Colin Nalder, Sara Alonso, Caroline Lamb, Margaret Bidmead, John Staffurth and David Dearnaley
Source of funding: The Royal Marsden, Varian Oncology Systems
A randomised trial is underway to treat patients with prostate cancer using a simple step and shoot technique. Recent studies on the radiobiology of prostate cancer have suggested that shorter courses of radiotherapy giving higher doses at each treatment (hypofractionated radiotherapy) may give improved cancer control for the same level of radiation related side effects. There are three arms to this trial to treat the prostate to 74, 60 and 57 Gy in 37, 20 and 19 fractions respectively. The aim is to treat the prostate PTV to the appropriate total dose and two additional margins of 5mm and 10mm to 96% and 80% respectively. A planning study was undertaken to investigate how these plans should best be carried out. It was found that a two segment technique using three or four gantry angles generally produced the isodose levels required. No extra quality assurance, beyond that usually done for conformal planning, is needed.

Return to Physics Home Page

Webpages updated 2005
Footer
 
Everyman - Funding research to cross out male cancer. News


Cooking recipes, secrets, methods and techniques - Cooking secrets is a free online cooking resource that aims to help cooks finding all recipes they need. Cooking recipes that taste great.
As your viewing these websites, another factor to consider is how their website is set up for a link exchange program. These software programs automatically search and send email requests for a link Exchange with other websites. Some link farms can have thousands of websites who have agreed to do a link exchange.